Phenserine Efficacy in Alzheimer's Disease
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
To gather preliminary evidence in Alzheimer's disease (AD) for the efficacy of phenserine, a non-competitive acetylcholinesterase inhibitor that has independent modulatory effects on amyloid-β generation, a 12-week comparison of patients receiving phenserine (10 and 15 mg BID) or placebo was conducted under double-blind conditions. Patients who completed 12 weeks of the double-blind before others were continued in the double-blind to determine longer-term treatment effects. At 12 weeks, mean ADAS-cog (AD assessment scale-cognitive) changes from baseline were -2.5 and -1.9 for high-dose phenserine (n=83) and placebo (n=81) groups, respectively, a non-statistically significant improvement for the high-dose phenserine group relative to placebo. CIBIC+ (clinician's interview based impression of change + caregiver's input) values for the high-dose and placebo groups were similar at 12 weeks. For patients who received more than 12 weeks of therapy, the ADAS-cog changes were -3.18 and -0.66 for the high-dose phenserine (n=52) and placebo (n=63) groups, respectively, a difference achieving statistical significance (p=0.0286). After 12 weeks, CIBIC+ values were 3.59 and 3.95 for the high-dose (n=54) and placebo (n=66) groups respectively (p=0.0568). These results from this short-term study are consistent with phenserine potentially benefiting mild to moderate Alzheimer's disease symptomatically but do not address possible amyloid metabolic mediated effects on disease processes in AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: APP binds DR6 to trigger axon pruning and neuron death via distinct caspases
Nikolaev, A., McLaughlin, T., O’Leary, D. D. M., & Tessier-Lavigne, M. (2009) · Nature · doi:10.1038/nature07767 · Cited by 992 · cited 1×
“Drug discovery strategies currently aim to lower oligomeric forms of Aβ by altering the activities of secretases (β and γ) able to cleave APP and generate Aβ [6,7,10,14] and other toxic APP products, such as C31 and N-APP [15,16].”
RetractedAlzheimer’s disease: Clinical trials and drug development
Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., & Kivipelto, M. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70119-8 · Cited by 1,217
Self-citationManagement of agitation and aggression associated with Alzheimer disease
Ballard, C. G., Gauthier, S., Cummings, J. L., Brodaty, H., Grossberg, G. T., Robert, P., & Lyketsos, C. G. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.39 · Cited by 404 · cited 1×
“…by deterioration of memory and cognitive functions, progressive impairments of daily activities, together with episodic neuropsychiatric symptoms [4, 5], spurred a drug discovery program within the Intra-mural Research Program of the National Institute of Aging (NIA) aimed at identifying a…”
Synaptic and Endosomal Localization of Active γ-Secretase in Rat Brain
Frykman, S., Hur, J.-Y., Frånberg, J., Aoki, M., Winblad, B., Nahalkova, J., Behbahani, H., & Tjernberg, L. O. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008948 · Cited by 57
Self-citationPei, J.-J., Sjögren, M., & Winblad, B. (2008) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e328314b78b · Cited by 49
Self-citation
Cited by
Cholinesterase inhibitors as Alzheimer's therapeutics (Review)
Sharma, K. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.10374 · Cited by 602
Walczak-Nowicka, Ł. J., & Herbet, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179290 · Cited by 335
Drug repositioning and repurposing for Alzheimer disease
Ballard, C., Aarsland, D., Cummings, J., O’Brien, J., Mills, R., Molinuevo, J. L., Fladby, T., Williams, G., Doherty, P., Corbett, A., et al. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0397-4 · Cited by 201
Old and new acetylcholinesterase inhibitors for Alzheimer’s disease
Galimberti, D., & Scarpini, E. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1216972 · Cited by 117
“At time of termination, 255 patients were randomized to double-blind, placebo-controlled treatment with phenserine at two dosing levels (10- and 15-mg BID) [4,5].”
BackgroundMethodBoada, M., López, O., Núñez, L., Szczepiorkowski, Z. M., Torres, M., Grifols, C., & Páez, A. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.01.001 · Cited by 91
“Hence, interfering with factors that regulate the amyloid precursor protein production may affect intracellular levels of amyloid precursor protein and thus reducing the overall levels of Ab [5,6].”
Background
Metadata
- Authors
- Winblad, B., Giacobini, E., Frölich, L., Friedhoff, L. T., Bruinsma, G., Becker, R. E., & Greig, N. H.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2011-01-07
- Volume
- 22
- Issue
- 4
- Pages
- 1201-1208
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1808821669
- Cited by
- 68
- References
- 5
- FWCI
- 3.47
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.